|
|
|
|
|
Candesartan
drug data and news
Candesartan drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Candesartan | ||
| Brand Names/Synonyms | Atacand; Blopress; CHEMBANK1631; Candesartan; Candesartan [Usan:Inn]; Candesartan/Cilexetil | ||
| Indication | For the treatment of hypertension. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Candesartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Candesartan does not have an active metabolite or possess uricosuric effects. | ||
| Mechanism Of Action | Candesartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. | ||
| Candesartan News (When available) |
Kidney Trouble Speeds Heart Failure Feb 6, 2006 Botox shots may help kids who have cerebral palsy Feb 12, 2006 Kidney Trouble Speeds Heart Failure Feb 6, 2006 Music, Healing Touch May Aid Recovery Jan 16, 2006 New Analysis of CHARM Programme Provides Key Insights into Patient ... Dec 7, 2005 Faithful Adherence to Placebo Is Predictive of Outcome Dec 7, 2005 Medication Adherence Linked to Improved Heart Failure Survival Dec 7, 2005 Chronic Heart Failure Patients Who Stick To Their Medication More ... Dec 9, 2005 Govt medicine spending slammed as 'pathetic' Dec 5, 2005 Medications Keep Heart-Failure Patients Alive Dec 6, 2005 Anti-depressant prescriptions rising Dec 5, 2005 Spending on target, patient numbers growing Dec 5, 2005 TAKEDA UK LTD RECOGNISED IN PRESTIGIOUS PHARMACEUTICAL INDUSTRY Dec 7, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 Angiotensin Blockade Alone Decreases Albuminuria in Children with ... Nov 17, 2005 Boost for dual heart failure approach Oct 18, 2005 Risk of heart attack and cardiovascular death significantly ... Oct 12, 2005 New Analysis of CHARM Program Published in JAMA Evaluates Effect ... Oct 11, 2005 AstraZeneca's Atacand cuts heart attack, death risk: study Oct 12, 2005 Risk of Heart Attack and Cardiovascular Death Significantly ... Oct 11, 2005 Takeda: an East wind blows good for Blopress Oct 13, 2005 Additional Indication of Blopress for the Treatment of Chronic ... Oct 11, 2005 Takeda gains approval to sell Bropress as heart failure treatment ... Oct 11, 2005 Risk of Heart Attack and Cardiovascular Death Significantly ... 11 Oct 2005 Additional Indication of Blopress for the Treatment of Chronic ... 11 Oct 2005 Takeda gains approval to sell Bropress as heart failure treatment ... 11 Oct 2005 CHARM Program Evaluates Effects of ATACAND(R) (candesartan ... Sep 6, 2005 (PRN) - Met-Pro Corporation's Systems Division Receives Equipment ... Sep 6, 2005 AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005 Strategies to Prevent Type 2 Diabetes Aug 12, 2005 Candesartan therapy can reduce the risk of diabetes in heart ... Jul 10, 2005 Candesartan Therapy Can Reduce the Risk of Diabetes in Heart ... Jul 6, 2005 PHARMAC welcomes increased budget for 2006 year Jul 25, 2005 "Diabesity" and Kidney Function Jul 19, 2005 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antihypertensive Agents; Angiotensin II Receptor Antagonists; ATC:C09CA06 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Candesartan: No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III). Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected. Lithiumó Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists. An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylicacid | ||
| Chemical Formula | C24H20N6O3 | ||
| Molecular Weight | 440.454 g/mol | ||
| Smiles String | CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 5.282 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 9 hours | ||
| Protein Binding [%] | >99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Candesartan.html http://www.rxlist.com/cgi/generic/candesar.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00420 | ||
| CAS Registry Number | 139481-59-7 | ||
| KEGG Compound ID | C07468 | ||
| PubChem ID | SID:208049 | ||
| PharmGKB ID | PA448765 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2239091 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |